342 related articles for article (PubMed ID: 25811654)
1. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.
Bolton KJ; McCaw JM; Brown L; Jackson D; Kedzierska K; McVernon J
PLoS One; 2015; 10(3):e0120138. PubMed ID: 25811654
[TBL] [Abstract][Full Text] [Related]
2. Recalling the Future: Immunological Memory Toward Unpredictable Influenza Viruses.
Auladell M; Jia X; Hensen L; Chua B; Fox A; Nguyen THO; Doherty PC; Kedzierska K
Front Immunol; 2019; 10():1400. PubMed ID: 31312199
[TBL] [Abstract][Full Text] [Related]
3. A Role of Influenza Virus Exposure History in Determining Pandemic Susceptibility and CD8+ T Cell Responses.
Quiñones-Parra SM; Clemens EB; Wang Z; Croom HA; Kedzierski L; McVernon J; Vijaykrishna D; Kedzierska K
J Virol; 2016 Aug; 90(15):6936-6947. PubMed ID: 27226365
[TBL] [Abstract][Full Text] [Related]
4. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease.
Herrmann VL; Hartmayer C; Planz O; Groettrup M
J Control Release; 2015 Oct; 216():121-31. PubMed ID: 26276509
[TBL] [Abstract][Full Text] [Related]
6. Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines.
Subramanian R; Graham AL; Grenfell BT; Arinaminpathy N
PLoS Comput Biol; 2016 Dec; 12(12):e1005204. PubMed ID: 27977667
[TBL] [Abstract][Full Text] [Related]
7. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.
Brown LE; Kelso A
Immunol Cell Biol; 2009; 87(4):300-8. PubMed ID: 19308073
[TBL] [Abstract][Full Text] [Related]
8. Toward a broadly protective influenza vaccine.
Doherty PC; Kelso A
J Clin Invest; 2008 Oct; 118(10):3273-5. PubMed ID: 18802488
[TBL] [Abstract][Full Text] [Related]
9. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.
Staneková Z; Varečková E
Virol J; 2010 Nov; 7():351. PubMed ID: 21118546
[TBL] [Abstract][Full Text] [Related]
10. Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.
Uchida T
Microbiol Immunol; 2011 Jan; 55(1):19-27. PubMed ID: 21175770
[TBL] [Abstract][Full Text] [Related]
11. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.
Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T
Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099
[TBL] [Abstract][Full Text] [Related]
12. Pediatric influenza vaccination: understanding the T-cell response.
Bodewes R; Fraaij PL; Osterhaus AD; Rimmelzwaan GF
Expert Rev Vaccines; 2012 Aug; 11(8):963-71. PubMed ID: 23002977
[TBL] [Abstract][Full Text] [Related]
13. Why Are CD8 T Cell Epitopes of Human Influenza A Virus Conserved?
Li ZT; Zarnitsyna VI; Lowen AC; Weissman D; Koelle K; Kohlmeier JE; Antia R
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626684
[TBL] [Abstract][Full Text] [Related]
14. Universal influenza vaccines: a realistic option?
de Vries RD; Altenburg AF; Rimmelzwaan GF
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S120-S124. PubMed ID: 27130671
[TBL] [Abstract][Full Text] [Related]
15. Modelling the strategies for age specific vaccination scheduling during influenza pandemic outbreaks.
Knipl DH; Röst G
Math Biosci Eng; 2011 Jan; 8(1):123-39. PubMed ID: 21361404
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).
Ennis FA; Cruz J; Jameson J; Klein M; Burt D; Thipphawong J
Virology; 1999 Jul; 259(2):256-61. PubMed ID: 10388649
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of multivalent H2 influenza pandemic vaccines in mice.
Lenny BJ; Sonnberg S; Danner AF; Friedman K; Webby RJ; Webster RG; Jones JC
Vaccine; 2017 Mar; 35(10):1455-1463. PubMed ID: 28189402
[TBL] [Abstract][Full Text] [Related]
18. Seasonality as a driver of pH1N12009 influenza vaccination campaign impact.
Bolton KJ; McCaw JM; Dafilis MP; McVernon J; Heffernan JM
Epidemics; 2023 Dec; 45():100730. PubMed ID: 38056164
[TBL] [Abstract][Full Text] [Related]
19. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.
Rimmelzwaan GF; Fouchier RA; Osterhaus AD
Curr Opin Biotechnol; 2007 Dec; 18(6):529-36. PubMed ID: 18083548
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.
Schmidt T; Dirks J; Enders M; Gärtner BC; Uhlmann-Schiffler H; Sester U; Sester M
Eur J Immunol; 2012 Jul; 42(7):1755-66. PubMed ID: 22585549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
